Prognostic scoring in colorectal cancer liver metastases: Development and validation

Archives of Surgery

Volumn 140, Issue 2, 2005, Pages 183-189

  Schindl, Martin ^a   Wigmore, Stephen J ^b   Currie, Elspeth J ^b   Laengle, Friedrich ^a   Garden, O James ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER RESECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SURVIVAL RATE; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 13644265525     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.140.2.183     Document Type: Article

References (41)

1. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
2. Nordlinger B, Guiguet M, Vaillant JC, et al; Association Francaise de Chirurgie. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254-1262.
3. Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg. 1997;173:467-471.
4. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291-299.
5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-321.
6. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-766.
7. Fong Y. Hepatic colorectal metastasis: current surgical therapy, selection criteria for hepatectomy, and role for adjuvant therapy. Adv Surg. 2000;34:351-381.
8. Rees M, Plant G, Bygrave S. Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg. 1997;84:1136-1140.
9. Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487-499.
10. Moroz P, Salama PR, Gray BN. Resecting large numbers of hepatic colorectal metastases. ANZ J Surg. 2002;72:5-10.
11. Lodge JP, Ammori BJ, Prasad KR, Bellamy MC. Ex vivo and in situ resection of inferior vena cava with hepatectomy for colorectal metastases. Ann Surg. 2000;231:471-479.
12. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy: an intergroup study. J Clin Oncol. 2002;20:1499-1505.
13. Giacchetti S. Chronotherapy of colorectal cancer. Chronobiol Int. 2002;19:207-219.
14. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
15. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663-669.
16. Doci R, Gennari L, Bignami P. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg. 1991;78:797-801.
17. Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994;116:703-711.
18. Ambiru S, Miyazaki M, Isono T, et al. Hepatic resection for colorectal metastases: analysis of prognostic factors. Dis Colon Rectum. 1999;42:632-639.
19. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg. 1999;86:332-337.
20. Mala T, Bohler G, Mathisen O, Bergan A, Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26:1348-1353.
21. Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati P. Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg. 2001;25:638-644.
22. Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg. 2000;231:59-66.
23. Tabachnick BG, Fidell LS. Using Multivariate Statistics for Social Sciences. 3rd ed. New York, NY: HarperCollins; 1996.
24. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
25. Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol. 1999;26:514-523.
26. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505-511.
27. Jatzko GR, Lisborg PH, Stettner HM, Klimpfinger MH. Hepatic resection for metastases from colorectal carcinoma: a survival analysis. Eur J Cancer. 1995;31A:41-46.
28. Yuste AL, Aparicio J, Segura A, et al. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer. 2003;2:231-234.
29. Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308-317.
30. Rougier P, Milan C, Lazorthes F, et al; Fondation Francaise de Cancerologie Digestive. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82:1397-1400.
31. Taylor I, Mullee MA, Campbell MJ. Prognostic index for the development of liver metastases in patients with colorectal cancer. Br J Surg. 1990;77:499-501.
32. Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999;79:1800-1805.
33. Kemeny MM, Hogan JM, Ganteaume L, Goldberg DA, Terz JJ. Preoperative staging with computerized axial tomography and biochemical laboratory tests in patients with hepatic metastases. Ann Surg. 1986;203:169-172.
34. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg. 2001;88:255-260.
35. Li X, Mortensen B, Rushfeldt C, Huseby NE. Serum γ- glutamyltransferase and alkaline phosphatase during experimental liver metastases: detection of tumour-specific isoforms and factors affecting their serum levels. Eur J Cancer. 1998;34:1935-1940.
36. Viot M, Thyss A, Schneider M, et al. Alpha 1 isoenzyme of alkaline phosphatases: clinical importance and value for the detection of liver metastases. Cancer. 1983;52:140-145.
37. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001;233:293-299.
38. Zealley IA, Skehan SJ, Rawlinson J, Coates G, Nahmias C, Somers S. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG PET. Radiographics. 2001;21:S55-S69.
39. Strasberg SM, Siegal BA. Survival of patients staged by FDG-PET before resection of hepatic metastases from colorectal cancer [letter]. Ann Surg. 2002;235:308-310.
40. Rohren EM, Paulson EK, Hagge R, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med. 2002;27:550-555.
41. Halkar RK, Toro JR, Lim EH, et al. Role of FDG-PET in the pre-operative evaluation of surgical resection of hepatic metastases from colorectal cancer [abstract]. Clin Positron Imaging. 1999;2:335.